Tonix Pharmaceuticals Holding Investor Presentation — March 2019 - Tonix Pharmaceuticals Holding Corp.

Document content

Version P0167 3-18-19 (Doc 0451)

Investor Presentation

Cautionary Note on Forward

Certain statements inthispresentation regarding strategic plans, expectations andobjectives forfuture

operations orresults are“forward -looking statements” asdefined bythePrivate Securities Litigation Reform

Actof1995.These statements may beidentified bytheuseofforward -looking words such as“anticipate,”

“believe,” “forecast,” “estimate” and“intend,” among others .These forward -looking statements arebased on

Tonix’s current expectations andactual results could differ materially .There areanumber offactors that

could cause actual events todiffer materially from those indicated bysuch forward -looking statements. These

factors include, butarenotlimited to,substantial competition ;ourneed foradditional financing ;uncertainties

ofpatent protection andlitigation ;uncertainties ofgovernment orthird party payor reimbursement ;limited

research anddevelopment efforts anddependence upon third parties ;andrisks related tofailure toobtain

U.S.Food andDrug Administration clearances orapprovals andnoncompliance withitsregulations .Aswith

anypharmaceutical under development, there aresignificant risks inthedevelopment, regulatory approval

andcommercialization ofnewproducts .Theforward -looking statements inthispresentation aremade asof

thedateofthispresentation, even ifsubsequently made available byTonix onitswebsite orotherwise .Tonix

does notundertake anobligation toupdate orrevise anyforward -looking statement, except asrequired by

law.Investors should read theriskfactors setforth intheAnnual Report onForm 10-Kfortheyear ended

December 31,2018, asfiledwiththeSecurities andExchange Commission (the“SEC”) onMarch 18,2019,

andperiodic reports andcurrent reports filedwiththeSEConorafter thedatethereof .AllofTonix's forward -

•A clinical stage pharmaceutical company dedicated to developing innovative

treatments for patients and making meaningful contributions to society

•Target therapeutics with high need for improvement

−Conditions with no or ineffective treatments

−Significant patient segments not well served by existing therapies

•Develop innovative treatment options with possibility to be a “game changer”

−Scientifically unique and innovative